Hematology

Patients with specific stem cell mutations may be at an increased risk of acute myeloid leukemia.

Protein once thought to suppress tumors in acute myeloid leukemia may instead promote the disease.

Promise seen in targeting protein in PTEN-deficient cancer cells.

TG Therapeutics’ investigational combination leukemia drug TG-1101 (ubilituximab), used with approved treatment Imbruvica (ibrutinib), showed positive results in a late-stage clinical trial.

Treatment with the myxoma virus reduced tumor burden and led to a modest decrease in disease progression in mice.

Top news of the week in oncology and cancer drug development.

PI3K inhibitors loaded into nanoparticles provided targeted treatment for head and neck cancers.

Drug may offer an effective alternative to chemotherapy for patients with leukemia.

Enasidenib is a targeted inhibitor of mutated isocitate dehydrogenase.

Investigational drug treats patients with relapsed or refractory AML with an isocitrate dehydrogenase 2 mutation.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

New technology can predict which patients will achieve remission and which will relapse.

Young children had more than twice the risk for overdose compared to children whose mothers were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) rather than opioids.

Top news of the week in oncology and cancer drug development.

The Akt protein is crucial for T cells to transform into memory T cells.

SF2523 can dually inhibit a protein and an enzyme associated with cancer.

Cancer cells adjusted to have normal circadian rhythm slowed tumor growth.

Tumor growth can be fueled by sleep disruption.

Extrachromosomal oncogene helps drive tumor evolution and heterogeneity.

Lenalidomide (Revlimid) maintenance improved survival in multiple myeloma patients following a stem cell transplant.

Revlimid is the only FDA-approved maintenance therapy for multiple myeloma following stem cell transplant.

Inotuzumab ozogamicin treats relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Inotuzumab ozogamicin was granted priority review in patients with acute lymphoblastic leukemia.

The FDA has accepted Pfizer’s biologics license application (BLA) and granted priority review for their experimental leukemia treatment.

Top news of the week in oncology and cancer drug development.